Asset

KER-047

Keros Therapeutics Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05927012phase2withdrawn2023-11-302025-08-29Keros Therapeutics, Inc.A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)